# Semaglutide for Weight Loss: Clinical Trial Evidence and Outcomes

> Semaglutide for weight loss: STEP 1 (14.9% at 68 weeks), STEP 5 two-year data (15.2%), STEP 2 in type 2 diabetes (9.6%), adolescent STEP TEENS data, body composition, and mechanism.

## Semaglutide weight loss outcomes in clinical trials

STEP 1 (N=1,961, adults with obesity, no type 2 diabetes, 68 weeks): mean body-weight reduction 14.9% with semaglutide 2.4 mg weekly versus 2.4% with placebo. 86.4% of semaglutide participants achieved ≥5% weight loss versus 31.5% with placebo; 50.5% achieved ≥15% versus 4.9% [1].

STEP 5 (104 weeks, two-year data): 15.2% mean weight reduction sustained; 52.1% achieving ≥15% and 36.1% achieving ≥20% reduction [2].

STEP 2 (adults with type 2 diabetes): 9.6% mean weight reduction at 68 weeks versus 3.4% placebo. HbA1c improved by 1.6 percentage points. 68.8% achieved ≥5% weight loss versus 28.5% placebo [5].

STEP TEENS (N=201, adolescents ages 12–17, 68 weeks): BMI reduction 16.1% versus 0.6% increase with placebo. 73% achieved ≥5% BMI reduction versus 18% placebo. Improvements in triglycerides (-28.4%), cholesterol, ALT [16].

**Can you lose weight on Semaglutide?** STEP 1 (2021, NEJM) reported mean 14.9% body weight reduction at 68 weeks with 2.4 mg weekly versus 2.4% with placebo [1].

**How much weight can you lose on Semaglutide?** STEP 1: mean 14.9% at 68 weeks; STEP 5 two-year: 15.2% sustained. ~50.5% of STEP 1 participants achieved ≥15%; 36.1% achieved ≥20% in STEP 5 two-year cohort [1, 2].

## Mechanisms underlying Semaglutide-induced weight reduction

Weight reduction operates through at least three concurrent mechanisms: CNS appetite suppression via GLP-1R activation in the hypothalamic arcuate nucleus (POMC/CART neuronal activation, NPY/AgRP inhibition), delayed gastric emptying, and potential direct effects on adipose tissue metabolism via AMPK/SIRT1 pathway and adipose browning [11].

**How does Semaglutide work for weight loss?** Primarily through CNS appetite suppression (hypothalamic arcuate nucleus and brainstem), delayed gastric emptying, and potential direct effects on lipid metabolism — collectively producing a sustained caloric deficit [11, 12].

## Body composition changes in Semaglutide research

STEP 1 DEXA substudy (N=140): fat mass decreased 19.3% total; visceral adipose tissue decreased 27.4%. Absolute lean body mass also decreased — 9.7% over 68 weeks. Lean-to-fat mass ratio improved by 0.23 overall [15].

Visceral adipose tissue declined 27.4% — proportionally greater than total fat mass reduction; the component most associated with cardiovascular and metabolic risk.

**Will Semaglutide reduce belly fat?** Imaging substudies of STEP 1 show visceral adipose tissue reductions of 27.4% alongside 19.3% total fat mass reduction; absolute lean body mass also decreases [15].

## Onset of Semaglutide effects in study populations

Body weight reductions were statistically detectable at week 4 in STEP 1 (initial 0.25 mg escalation phase). Peak efficacy at the 2.4 mg maintenance dose observed between weeks 52–68. Glycemic effects appear within 24–48 hours of first dose; HbA1c improvements documented at weeks 2–4 in SUSTAIN-1 data [1].

Steady-state plasma concentrations require 4–5 weeks to achieve with once-weekly dosing [10].

**When does Semaglutide start working?** Pharmacodynamic effects measurable within 24–48 hours of first dose; body weight changes statistically detectable at week 4 in STEP 1; clinically meaningful weight loss (≥5%) first observed at median week 16–20 in trial populations [1].

## References

[1] Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
[2] Garvey WT, et al. STEP 5 two-year. Nat Med. 2022;28(10):2083-2091. DOI: 10.1038/s41591-022-02026-4
[5] Davies M, et al. STEP 2. Lancet. 2021;397(10278):971-984. DOI: 10.1016/S0140-6736(21)00213-0
[10] Yang X-D, Yang Y-Y. Clinical Pharmacokinetics of Semaglutide. Drug Des Devel Ther. 2024;18:2555-2569. DOI: 10.2147/DDDT.S470826
[11] Tamayo-Trujillo R, et al. Molecular mechanisms of semaglutide. Front Nutr. 2024;11:1398059. DOI: 10.3389/fnut.2024.1398059
[12] Papakonstantinou I, et al. Spotlight on Mechanism. Curr Issues Mol Biol. 2024;46(12):13632-13656. DOI: 10.3390/cimb46120872
[15] Wilding JPH, et al. Body Composition, STEP 1. J Endocr Soc. 2021. DOI: 10.1210/jendso/bvab048.030
[16] Weghuber D, et al. STEP TEENS. N Engl J Med. 2022;387(24):2245-2257. DOI: 10.1056/NEJMoa2208601

---

A trial-by-trial weighing of the semaglutide evidence record — STEP, SUSTAIN, SELECT, PIONEER — reported plainly, cited fully, and sold by no one.